

Steps before prequalification

I. BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Lupin Limited, Mumbai, India submitted in 2002 an application for [TB070 trade name]* (TB070) to be assessed with the aim of including [TB070 trade name] in the list of prequalified medicinal products for the initial treatment of tuberculosis.

[TB070 trade name] was assessed according to the 'Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies' by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

2. Steps taken in the evaluation of the product

August 2002	During the meeting of the assessment team the quality data were reviewed and further information was requested.
September 2002	During the meeting of the assessment team the safety and efficacy data were reviewed and further information was requested
November 2002	In between the meetings of the assessment team the applicant's response letter was received. The additional quality data were reviewed and further information was requested.
January 2003	In between the meetings of the assessment team the applicant's response letter was received. The additional safety and efficacy data were reviewed and further information was requested.
January 2003	The applicant's response letters were received.
January 2003	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
May 2003	During the meeting of the assessment team the additional safety and efficacy data were reviewed and further information was requested
May 2003	In between the meetings of the assessment team the applicant's response letter was received. The quality data were reviewed and found to comply with the relevant WHO requirements.
September 2003	In between the meetings of the assessment team the applicant's response letter was received. The quality data were reviewed and found to comply with the relevant WHO requirements
13 November 2003	[TB070 trade name] was included in the list of prequalified medicinal products.

II. GENERAL CONDITIONS FOR THE PREQUALIFICATION

1. Manufacturer and Inspection status

Manufacturer of the finished product and responsible for batch release

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Ethambutol hydrochloride/ isoniazid/
pyrazinamide/ rifampicin 275mg/ 75mg/
400mg/ 150mg tablets, (Lupin Ltd), TB070

WHOPAR Part 7

July 2022

Lupin Limited
A-28/1, MIDC Industrial Area
Chikalthana
Aurangabad 431 210
India

Lupin Limited
EPIP, SIDCO Industrial Complex
Kartholi, Bari Brahmana
Jammu & Kashmir
181133 India
Tel: +91-1923 220046/220672/22076
Fax: +91-1795 661452

Inspection status

The sites inspected were found to be in compliance with WHO requirements for GMP, GLP and GCP.

2. (Advice on) Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

Further information is available at:

<https://extranet.who.int/pqweb/medicines/prequalified-lists/finished-pharmaceutical-products>